CXCL9 and colorectal carcinoma: In conclusion, D594A mutation in CRC can remodel the TIME, including upregulated the expression of PD-L1 and MHC class I, and recruit increased number of CD8+ T cells partially via increasing THBS1 mediated CXCL9/CXCL10 release, which can enhance antitumor potency with ICIs therapy (Fig. 8D).